GILEAD SCIENCES INC | 53,26 Euro | +0,60 +1,14 % | |
| WKN: 885823 ISIN: US3755581036 Ticker-Symbol: GIS | Frankfurt | 05.12.13 | 09:52 Uhr |
Branche PharmaAktienmarkt NASDAQ-100S&P 100 S&P 500 NASDAQ Biotech |
|
|
Aktuelle News zu GILEAD SCIENCES
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
| Leser | Medien | |
|---|---|---|---|---|
| Mi | Gilead CEO John Martin pockets $19 million in stock sale | 18 | bizjournals | |
--> Artikel lesen | ||||
| Mi | Update on Gilead's Legal Troubles | 34 | Zacks | |
--> Artikel lesen | ||||
| Di | Watch for Gilead Sciences to Potentially Rebound After Falling 2.82% Yesterday | 19 | SmarTrend | |
--> Artikel lesen | ||||
| Di | SmarTrend Watching for Potential Rebound in Shares of Gilead Sciences After 2.82% Loss | 12 | SmarTrend | |
--> Artikel lesen | ||||
| Di | Gilead Sciences Bearish Moving Average Crossover Alert | 27 | SmarTrend | |
--> Artikel lesen | ||||
| Di | Idenix files patent infringement and interference lawsuits against Gilead Sciences | 26 | Pharma Bus Review | |
--> Artikel lesen | ||||
| Di | Gun Patents, Idenix-Gilead, Sony, Amazon: Intellectual Property | 29 | Bloomberg | |
--> Artikel lesen | ||||
| Mo | Gilead Sciences to Present at the NASDAQ OMX 30th Investor Program on Tuesday, December 3 | 18 | Business Wire | |
| Webcast Available Through Gilead Corporate Website Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate presentation will be webcast from the NASDAQ OMX 30th Investor... --> Artikel lesen | ||||
| Mo | Idenix files suits against Gilead on eve of expected drug approval | 16 | bizjournals | |
--> Artikel lesen | ||||
| Mo | Idenix Files Patent Infringement, Interference Lawsuits Against Gilead | 23 | AFX News | |
| FOSTER CITY (dpa-AFX) - Idenix Pharmaceuticals, Inc. (IDIX) said Monday that it has filed a patent infringement lawsuit in the United States District Court in Boston, Massachusetts and a separate... --> Artikel lesen | ||||
| Mo | Market Expert Opinion: Gilead Sciences, NPS Pharma, InterMune, and Halozyme Therapeutics | 46 | PR Newswire | |
| LONDON, December 2, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
On Friday, November 29, 2013, the S&P 500 Healthcare sector index ended the... --> Artikel lesen | ||||
| Mo | Gilead Sciences, Inc. Uses the PHT Corporation LogPad System for 1st Antianginal Drug to Treat Type 2 Diabetes | 14 | Business Wire | |
| World's most widely used ePRO System leveraged on 14-country, 104-site, 927-patient trial; primary and secondary endpoints achieved, with 98% patient compliance The PHT Corporation... --> Artikel lesen | ||||
| Mo | Idenix Pharmaceuticals Files Patent Infringement, Interference Lawsuits Against Gilead Sciences | 6 | Benzinga.com | |
--> Artikel lesen | ||||
| Mo | Idenix Pharma Files Two New Patent Suits Against Gilead | 12 | StreetInsider.com | |
--> Artikel lesen | ||||
| 28.11. | Gilead Sciences, Inc. is the Focus of this Week's Ubika Mutual Fund - Top Holdings Report | 74 | Newsfile | |
| Toronto, Ontario--(Newsfile Corp. - November 28, 2013) - Ubika Research has released the next report in the "Ubika Mutual Fund - Top Holdings" series. This week's top holding is Gilead Sciences, Inc.... --> Artikel lesen | ||||
| 27.11. | Biotech Stock Roundup: EU News Boosts Biogen, Gilead & Celgene | 68 | Zacks | |
--> Artikel lesen | ||||
| 27.11. | Product Reviews, Recognitions, FDA Responses, and New Leadership Appointments - Research Report on Gilead, WellPoint, Questcor, Forest Laboratories, and Envision Healthcare | 18 | PR Newswire | |
| NEW YORK, November 27, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Gilead... --> Artikel lesen | ||||
| 27.11. | Profits drop by 9.5pc at Gilead's Irish arm | 20 | Irish Independent | |
--> Artikel lesen | ||||
| 26.11. | New Hepatitis C Drug Success Should Drive Gilead Sciences In 2014 | 31 | Seeking Alpha | |
--> Artikel lesen | ||||
| 26.11. | Jefferies Group Increases Gilead Sciences Price Target to $80.00 | 17 | i3investor.com | |
--> Artikel lesen |
Seite:
1 2 3 4 5 Weiter >>
401 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | |
|---|---|---|---|---|
| NOVO NORDISK | 129,95 | +0,73 % | Events, Marketing Recommendation, FDA Meeting, and Marketing Authorization - Research Report on Hospira, Novo Nordisk, Repros Therapeutics, GW Pharmaceuticals, and Envision Healthcare | |
| NEW YORK, December 2, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Hospira Inc. (NYSE: HSP), Novo Nordisk A/S (NYSE: NVO), Repros Therapeutics Inc. (NASDAQ:... --> Artikel lesen | ||||
| CELGENE | 117,56 | +0,91 % | OncoMed, Celgene To Jointly Advance Multiple Anti-Cancer Stem Cell Therapeutics | |
| SUMMIT (dpa-AFX) - OncoMed Pharmaceuticals, Inc. (OMED) and Celgene Corp. (CELG) announced an agreement to jointly develop and commercialize up to six anti-cancer stem cell or CSC product... --> Artikel lesen | ||||
| STADA ARZNEIMITTEL | 35,50 | -3,19 % | DGAP-Gesamtstimmrechtsmitteilung: STADA Arzneimittel AG (deutsch) | |
| STADA Arzneimittel AG: Veröffentlichung der Gesamtzahl der
Stimmrechte nach § 26a WpHG mit dem Ziel der europaweiten
Verbreitung
STADA Arzneimittel AG / Veröffentlichung der Gesamtzahl der
Stimmrechte
29.11.2013... --> Artikel lesen | ||||
| PFIZER | 22,856 | +0,27 % | Pfizer könnte nochmal durchstarten | |
| Uns gefällt der aktuelle Trend des Pharmazieherstellers Pfizers. Der Trend zeigt aktuell eindeutig nach oben und nach einem doch recht starkem Anstieg, hat sich die Aktie in den letzten Wochen eine... --> Artikel lesen | ||||
| NOVARTIS | 57,42 | +0,02 % | Novartis-CEO äussert sich zum Rivalen Roche | |
| Zürich (awp) - Der Chef des Pharmakonzerns Novartis, Joseph Jimenez, hält an den getrennten Wegen von Novartis und Roche fest. "Zwei sehr erfolgreiche Gesundheitsunternehmen in der Schweiz zu haben... --> Artikel lesen | ||||
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von